4X
4XB.F XBiotech Inc
- Market cap
- EUR 52.4M
- P/E
- -
- P/B
- 0.45x
- ROE
- -19.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4XB.F undervalued?
Graham numberThe Graham number of XBiotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XBiotech Inc fundamental analysis
No fundamental analysis for XBiotech Inc yet.
XBiotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and gener…
Full company profileXBiotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XBiotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 12.7M | 44.0M | 18.4M | 4.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | 9.45M | 12.6M | 3.36M | 0.00 | - | - | - |
| Operating Income | -52.8M | -34.1M | -21.0M | -31.2M | -18.3M | -25.1M | -34.5M | -37.5M | -42.5M | -55.7M | -24.8M |
| EBITDA | - | -32.6M | -18.6M | -28.9M | -16.0M | -22.4M | -31.9M | -22.6M | -36.0M | -43.5M | -23.0M |
| Net Income | -52.8M | -33.2M | -21.1M | 669M | -11.2M | -17.4M | -32.9M | -24.6M | -38.5M | -45.5M | -24.5M |
| EPS | - | -0.94 | -0.59 | 16 | -0.38 | -0.57 | -1.08 | -0.81 | -1.26 | -1.49 | -0.80 |
| Balance Sheet | |||||||||||
| Total Assets | 67.1M | 63.0M | 44.3M | 817M | 354M | 275M | 246M | 227M | 199M | 150M | 134M |
| Total Liabilities | 7.99M | 2.81M | 2.95M | 61.2M | 5.11M | 5.79M | 5.70M | 7.77M | 16.8M | 9.73M | 5.19M |
| Shareholders' Equity | 59.1M | 60.2M | 41.4M | 756M | 349M | 269M | 240M | 219M | 182M | 140M | 128M |
| Cash & Short-term Investments | 34.3M | 31.8M | 15.8M | 715M | 237M | 237M | 157M | 200M | 173M | 126M | 110M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -46.0M | -33.6M | -16.5M | -18.3M | -65.1M | 69.4M | -14.8M | -18.7M | -31.0M | -39.9M | -27.0M |
| Capital Expenditure | 13.9M | 1.41M | 122K | 204K | 3.73M | 3.53M | 585K | 362K | 1.30M | 289K | 0.00 |
| Free Cash Flow | - | -35.1M | -16.7M | -18.5M | -68.9M | 65.9M | -15.4M | -19.1M | -32.3M | -40.2M | -27.0M |
| Ratios | |||||||||||
| ROE | -89.3% | -55.1% | -51.1% | 88.5% | -3.2% | -6.5% | -13.7% | -11.2% | -21.1% | -32.4% | -19.0% |
| ROA | -78.7% | -52.6% | -47.7% | 81.9% | -3.2% | -6.3% | -13.4% | -10.8% | -19.4% | -30.3% | -18.3% |
| Net Profit Margin | - | - | - | 5,272.7% | -25.5% | -94.7% | -820.4% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
XBiotech Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 15, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 75.0M | 2.46 | - |
| 2020 | USD 75.0M | 2.56 | - |
| 2019 | USD 75.0M | 1.81 | 11.2% |
| 2018 | USD 75.0M | 2.09 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns XBiotech Inc
- Insiders 38.08%
- Institutions 6.70%
- Public & others 55.23%
- Shares outstanding 30.5M
- Free float 18.6M
XBiotech Inc company profile
- Company name
- XBiotech Inc
- Ticker
- 4XB.F
- ISIN
- CA98400H1029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 5217 Winnebago Lane, Austin, TX, United States, 78744
- Phone
- 512 386 2900
- Website
- xbiotech.com
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
XBiotech Inc management
5- Mr. John SimardFounder & Chairman · born 1962
- Dr. Sushma Shivaswamy Ph.D.Co-CEO & Chief Scientific Officer · born 1978
- Ms. Angela HuDirector of Finance · born 1984
- Mr. Jan-Paul SimardCo-Chief Executive Officer · born 2002
- Dr. Qian WuSenior Vice President of Clinical Operations & Analytical Quality